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Inflammatory bowel disease (IBD), clinically 
comprising Crohn’s disease (CD), and ulcer-
ative colitis (UC) are chronic inflammatory dis-
orders of the gut with complex etiologies 
(Kaser et al., 2010). The understanding of 
pathogenic mechanisms underlying the devel-
opment of IBD has aided the development of 
novel biological therapies. Agents that block the 
TNF pathways have been particularly success-
ful in IBD therapy (Melmed and Targan, 2010). 
However, a large proportion of patients either 
fail to respond or develop tolerance to TNF 
therapy, highlighting the need for new thera-
peutic targets (Baumgart and Sandborn, 2007).
IL-1 is a proinflammatory cytokine with a 
wide range of systemic and local effects. Primar-
ily produced by innate leukocytes, IL-1 can 
modulate the function of both immune and 
nonimmune cells. Stimulation with IL-1 pro-
motes the activation and effector functions of 
dendritic cells, macrophages, and neutrophils 
(Dinarello, 1996). Moreover, IL-1 can induce 
neutrophilia and promote neutrophil migration 
(Dinarello, 2009). IL-1 promotes T cell activa-
tion and survival (Ben-Sasson et al., 2009) and 
has recently been shown to act in concert with 
other proinflammatory cytokines to promote 
the differentiation of CD4+ Th17 cells (Sutton 
et al., 2006, 2009; Acosta-Rodriguez et al., 
2007; Chung et al., 2009). The potent inflam-
matory activity of IL-1 is reflected by the tight 
mechanisms in place to regulate its secretion. 
IL-1 is translated as an inactive 31 kD precur-
sor (pro-IL-1) after TLR stimulation, which is 
cleaved into its activated 17 kD form by caspase-1, 
also known as interleukin-1 converting en-
zyme (ICE; Thornberry et al., 1992). Activation 
of caspase-1 relies on the formation of a multi-
molecular scaffold known as the inflammasome, 
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conditional deletion of the transcription factor Stat3 in regu-
latory Foxp3+ T cells (Chaudhry et al., 2009). Th17 cells are 
enriched in the inflamed gut both in animal models and in 
humans (Fujino et al., 2003; Nielsen et al., 2003; Hue et al., 
2006; Kullberg et al., 2006) and T cells lacking the transcrip-
tion factor ROR, that directs Th17 differentiation, could 
not transfer colitis to C57BL/6 Rag1/ mice (Leppkes et al., 
2009). However, T cell–derived IL-17A is not absolutely re-
quired for the development of intestinal pathology in T cell 
transfer models of colitis and it has been proposed that T cell–
derived IL-17A and IL-17F might play a redundant role in 
driving intestinal inflammation (Izcue et al., 2008; Leppkes 
et al., 2009; O’Connor et al., 2009). These conflicting results 
might be explained by an as yet undiscovered additional patho-
genic function of Th17 cells. Alternatively, a complex network 
of proinflammatory cells may contribute to IL-17A–mediated 
pathology in vivo (Littman and Rudensky, 2010).
In this study, we aimed to assess the role of IL-1 in chronic 
intestinal inflammation. As a result of the pluripotent activity 
of IL-1, we used complementary animal models of chronic 
colitis to selectively analyze the effects of IL-1 on adaptive 
and innate immune-mediated intestinal inflammation. Our re-
sults show that IL-1 signals are required for the development 
of severe inflammation in both T cell–independent and T cell–
mediated colitis. Moreover, we identified key mechanisms un-
derlying the pathogenic function of IL-1, including a central 
role for this cytokine in promoting the accumulation of 
IL-17A–producing innate and adaptive immune cells.
RESULTS
IL-1 plays a key role in innate intestinal inflammation
To specifically analyze the role of IL-1 in modulating innate 
inflammatory responses in the intestine, we infected T cell– and 
which is triggered by the activation of intracellular NOD-like 
receptors (NLR) by endogenous or exogenous danger signals 
(Martinon et al., 2009). Upon secretion into the extracellular 
space, IL-1 binds and signals via the IL-1 receptor 1 (IL-1R1), 
which is expressed on a wide range of cell types, including epi-
thelial and endothelial cells, hepatocytes, and innate and adap-
tive leukocytes (Sims and Smith, 2010). Regulatory mechanisms 
downstream of IL-1 secretion are also in place to limit the 
action of IL-1, including the production of a natural antago-
nist for its receptor, IL-1RA, and the expression of a decoy 
receptor, IL-1R2 (Dinarello, 1996).
Several clinical studies have reported high levels of IL-1 
secretion by colon lamina propria monocytes from patients 
with active IBD (Satsangi et al., 1987; Mahida et al., 1989; 
Ligumsky et al., 1990; Reinecker et al., 1993; McAlindon et al., 
1998). IL-1 levels in the colon correlated with disease activity 
and high levels of IL-1 were associated with active lesions 
(Casini-Raggi et al., 1995; Ludwiczek et al., 2004), suggesting 
an important role of this cytokine in promoting localized in-
flammation. High levels of colonic IL-1 are also a feature of 
many animal models of colitis (Cominelli et al., 1990; Okayasu 
et al., 1990; McCall et al., 1994), and treatment with IL-1–block-
ing agents has been successful in ameliorating acute models of 
intestinal injury and inflammation (Thomas et al., 1991; 
Cominelli et al., 1992; Siegmund et al., 2001). Furthermore, dif-
ferent genetic lesions associated with IBD development in ani-
mal models are associated with increased IL-1. For example, 
macrophages from knock-in mice bearing the most common 
CD-associated variant of the Nod2 gene produced high levels of 
IL-1 after stimulation with muramyl dipeptide (MDP; Maeda 
et al., 2005). These NOD2 mutant mice also developed exacer-
bated disease in response to acute dextran sulfate sodium (DSS)–
induced intestinal injury, which was significantly ameliorated by 
the administration of recombinant IL-1RA (Maeda et al., 2005). 
In addition, conditional deletion of the CD-linked autophagy 
gene Atg16l1 in the hematopoietic system of mice resulted in 
increased IL-1 production after LPS stimulation and increased 
susceptibility to DSS-mediated intestinal injury, a phenotype re-
versed by co-treatment with IL-18 and IL-1 antibodies 
(Saitoh et al., 2008). The importance of IL-1 in modulating 
intestinal inflammation has been confirmed by infection studies, 
as blocking IL-1 ameliorated inflammatory pathology in both 
Clostridium difficile–associated colitis and Salmonella typhimurium–
induced enteritis (Müller et al., 2009; Ng et al., 2010).
Although IL-1 has been linked to Th17 cell responses, 
the role of IL-17A in the development of intestinal inflam-
mation is controversial. In acute models of intestinal injury, 
IL-17A plays a disease protective role, with Il17a/ mice 
showing increased pathology and leukocyte infiltration after 
DSS administration (Ogawa et al., 2004). However, studies 
in chronic inflammatory models have highlighted a more 
complex role for IL-17A. Studies from our laboratory dem-
onstrated a pathogenic role for IL-17A in Helicobacter hepaticus 
(H. hepaticus)–driven innate immune IBD (Buonocore et al., 
2010). Similarly, administration of an IL-17A antibody 
ameliorated the spontaneous colitis developed by mice bearing a 
Figure 1. H. hepaticus–induced innate immune driven typhlocolitis 
is associated with IL-1 secretion. 129SvEv Rag2/ mice were in-
fected with H. hepaticus and sacrificed >8 wk after infection. (A) IL-1 
secretion from organ explants from colon, cecum, and ileum incubated 
overnight in complete medium. Results are shown as mean ± SEM (n = 3 
for uninfected control and n = 14 for H. hepaticus–infected mice, pooled 
from 2 independent experiments). (B) IL-1 levels in the supernatants of 
cLPLs cultured overnight in complete media. Results are shown as mean ± 
SEM (n = 7 for uninfected controls and n = 22 for H. hepaticus-infected 
mice, pooled from 3 separate experiments). **, P < 0.01.
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of IL-1 secretion in the lamina propria in IBD patients 
(Mahida et al., 1989; McAlindon et al., 1998). We observed 
high levels of IL-1 secretion by purified colonic lamina pro-
pria leukocytes (cLPLs) of H. hepaticus–infected 129SvEv 
Rag2/ mice (Fig. 1 B), confirming that chronic intestinal 
inflammation correlates with increased local secretion of 
IL-1 by innate leukocytes.
To formally assess the requirement for IL-1 in H. hepaticus– 
induced innate intestinal inflammation, we blocked the activ-
ity of IL-1 with a neutralizing monoclonal antibody (IL-1). 
Treatment of H. hepaticus–infected 129SvEv Rag2/ mice 
with IL-1 resulted in significant attenuation of colitis 
(Fig. 2, A–C), without affecting H. hepaticus colonization 
(unpublished data). Although cecal inflammation was not 
significantly attenuated (not depicted), hepatic inflammation 
was also reduced by administration of IL-1, as illustrated 
by the decreased number of inflammatory foci (Fig. 2 C). 
B cell–deficient 129SvEv Rag2/ mice with H. hepaticus, 
which results in the development of colonic and cecal in-
flammation that is entirely dependent on innate immunity 
(Erdman et al., 2003; Maloy et al., 2003). We first examined 
whether H. hepaticus–induced intestinal inflammation was 
associated with increased levels of active IL-1 by analyzing 
the levels of IL-1 secretion by organ explants from the gas-
trointestinal tract of H. hepaticus–infected 129SvEv Rag2/ 
mice. Intestinal inflammation in the colon and cecum of 
H. hepaticus–infected 129SvEv Rag2/ mice was associated 
with high levels of secreted IL-1 (Fig. 1 A). In contrast, no in-
crease in IL-1 levels was observed in the ileum of H. hepaticus–
infected 129SvEv Rag2/ mice (Fig. 1 A). Given that 
both colonization and H. hepaticus–induced inflammation 
occur primarily in the colon and cecum, this result suggests 
that IL-1 secretion is directly linked to local intestinal in-
flammation. Innate leukocytes appear to be the major source 
Figure 2. IL-1 drives innate immune colitis. 129SvEv Rag2/ mice were infected with H. hepaticus, treated weekly with 1 mg of IL-1 antibody 
or isotype control (i.p.), and sacrificed after 8 wk of infection. (A) Scores of colon inflammation. Each symbol represents an individual mouse, and data are 
pooled from four independent experiments. Bars represent the mean histological score for each group. (B) Spleen weights and splenocyte numbers.  
(C) Representative photomicrographs of mid-colon and liver sections. Bars, 200 µm. (D) Colonic lamina propria leukocytes were isolated from the described 
mice groups and cytokine secretion after overnight culture in complete media was determined. Data are shown as mean ± SEM from 3 pooled indepen-
dent experiments (n = 9–16). (E) Cytokine concentration in blood serum (mean ± SEM, n = 6–10 from 2 pooled independent experiments). ND, not detect-
able; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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We observed significantly decreased numbers of ILCs in 
the colons of H. hepaticus–infected 129SvEv Rag2/ mice 
that received IL-1 compared with those treated with an 
isotype control (Fig. 4 B). During H. hepaticus–induced 
intestinal inflammation, ILCs produce the proinflammatory 
cytokines IL-17A and IFN-, and these responses are enhanced 
Moreover, systemic inflammation was also reduced after 
IL-1 blockade, as shown by decreased splenomegaly and 
spleen cellularity in IL-1–treated animals (Fig. 2 B). 
These results identify a role for IL-1 in promoting intesti-
nal and systemic innate inflammation after H. hepaticus in-
fection. To further characterize the effect of blocking IL-1, 
we examined the levels of proinflammatory cytokines se-
creted by purified cLPLs from the different treatment groups 
(Fig. 2 D). As expected (Hue et al., 2006), we observed an 
increase in proinflammatory cytokine production by cLPLs 
from H. hepaticus–infected colitic mice. After administration 
of IL-1, we observed significantly decreased levels of IL-6, 
IFN-, IL-17A, and IL-1 when compared with isotype 
control–treated animals (Fig. 2 D). In addition, significantly 
increased levels of IL-6 were detected in the serum of 
H. hepaticus–infected animals, and these were markedly re-
duced by IL-1 treatment (Fig. 2 E). These results support 
a crucial role of IL-1 in promoting proinflammatory cyto-
kine cascades in innate immune colitis.
IL-1 blockade decreases granulocyte recruitment  
and accumulation of IL-17A–producing  
innate lymphoid cells in the colon
H. hepaticus–induced innate colitis is associated with pro-
nounced accumulation of proinflammatory CD11b+Gr1Hi 
granulocytes in the colon and spleen of infected mice (Hue 
et al., 2006). Thus, we isolated leukocytes from different 
tissues of H. hepaticus–infected IL-1–treated and isotype 
control-treated 129SvEv Rag2/ mice and analyzed the 
frequency of granulocytes by flow cytometry. As expected, 
H. hepaticus–mediated inflammation was associated with an 
increase in the frequency of CD11b+Gr1Hi cells in the colon 
and spleen (Fig. 3, A and B). Blocking IL-1 in H. hepaticus–
infected 129SvEv Rag2/ resulted in a decrease in the fre-
quency of CD11b+Gr1Hi granulocytes in the colon, although 
it did not affect frequencies in the spleen (Fig. 3, A and B). 
IL-1 promotes neutrophil recruitment by inducing the 
expression of C-X-C chemokines in vivo (Calkins et al., 2002). 
Accordingly, we observed a significant down-regulation of 
Cxcl1 (KC), Cxcl2 (MIP2), and Cxcl5 (ENA78) in the colon 
of H. hepaticus–infected 129SvEv Rag2/ mice treated with 
IL-1, compared with H. hepaticus–infected mice receiv-
ing an isotype control (Fig. 3 C). These data highlight an 
intestine-specific role of IL-1 in promoting the recruit-
ment of proinflammatory innate immune cell populations 
through the induction of chemokine expression.
We recently identified a novel population of Rort+ 
Sca1+ Thy1.2Hi innate lymphoid cells (ILCs) that play an im-
portant role in innate immune-mediated intestinal inflamma-
tion (Buonocore et al., 2010). Expression analysis revealed 
that ILCs isolated from the large intestine of H. hepaticus–
infected 129SvEv Rag2/ mice express high levels of the 
IL-1 receptor IL-1R1 (Fig. 4 A), suggesting that ILCs can 
directly be modulated by IL-1 in vivo. Thus, we analyzed 
the number and function of these cells in the colon after 
IL-1 treatment compared with isotype control–treated mice. 
Figure 3. Blocking IL-1 impairs the accumulation of proinflam-
matory CD11b+Gr1Hi granulocytes in the inflamed colon. 129SvEv 
Rag2/ mice were infected with H. hepaticus, treated weekly with 1 mg 
of IL-1 antibody or isotype control (i.p.), and sacrificed after 8 wk of 
infection. (A) Leukocytes were isolated from the colon and spleen, and the 
frequency of CD45+CD11b+Gr1Hi cells was assessed by flow cytometry 
(mean ± SEM from 3 pooled independent experiments, n = 9–16).  
(B) Representative FACS plots from the data presented in A (gated on 
CD45+ cells). (C) Colon chemokine expression as evaluated by qRT-PCR on 
total colon homogenates (mean ± SEM, n = 6–12 from 2 pooled indepen-
dent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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ILCs from the large intestines of H. hepaticus–infected 129SvEv 
Rag2/ mice were cultured with IL-1 and IL23r expres-
sion assayed using qRT-PCR. ILCs that were cultured with 
IL-1 expressed higher levels of IL23r than those cultured 
in medium alone, whereas the levels of expression of the 
transcription factor Rort did not change upon culture with 
IL-1 (Fig. 4 F). Conversely, culture with IL-23 did not sig-
nificantly enhance Il1r1 expression by ILCs (Fig. 4 G). Coll-
ectively, these data indicate that IL-1 plays multiple roles 
in promoting innate immune responses in the colon by 
modulating recruitment, accumulation, and function of key 
proinflammatory cell types.
T cell–specific IL-1R1 signaling drives  
T cell–mediated intestinal inflammation
We next addressed whether IL-1 could also promote dele-
terious adaptive immune responses within the intestine. To 
this end, we used the T cell transfer model of colitis in which 
transfer of naive CD4+ T cells to a lymphopenic host results 
after stimulation with IL-23 (Buonocore et al., 2010). Intracell-
ular cytokine staining revealed that the observed decrease in 
ILC number in the colon after IL-1 treatment was ac-
companied by a significant decrease in IL-17A–producing 
ILCs and by a reduction in the number of IFN-–producing 
ILCs (Fig. 4 C). These results indicate a role of IL-1 in 
promoting the accumulation and activation of ILCs in the 
colon. As we have shown that ILCs are the major IL-23–
responsive population in this innate colitis model (Buonocore 
et al., 2010), we cultured cLPLs from IL-1–treated, 
H. hepaticus–infected 129SvEv Rag2/ mice in the presence 
of IL-23. Blockade of IL-1 in vivo resulted in decreased 
production of both IL-17A and IFN- by IL-23–stimulated 
cLPLs in vitro (Fig. 4 D). Consistent with this reduced 
response to IL-23, cLPLs isolated from IL-1–treated 
H. hepaticus–infected 129SvEv Rag2/ exhibited reduced 
IL23r expression compared with those isolated from mice 
receiving an isotype control (Fig. 4 E). To test whether IL-1 
directly regulated IL23r expression by ILCs, FACS sorted 
Figure 4. IL-1 treatment reduces the 
accumulation of IL-17A–producing ILCs in 
the colon. (A) IL-1R1 expression by 
Sca1+Thy1.2Hi ILCs and rest of large intestine 
lamina propria cells. 129SvEv Rag2/ mice 
were infected with H. hepaticus and sacrificed 
after >8 wk of infection. LPLs were isolated 
from the large intestine, Sca1+Thy1.2Hi ILCs 
were FACS sorted, and Il1r1 expression was 
evaluated by qRT-PCR (mean ± SEM, n = 2 
from 2 independent experiments; 8–10 mice 
were pooled in each experiment). (B–E) 129SvEv 
Rag2/ mice were infected with H. hepaticus 
and treated weekly with 1 mg of IL-1 anti-
body or isotype control (i.p.). After 8 wk, mice 
were sacrificed and cLPLs were isolated.  
(B) Total numbers of Sca1+ Thy1.2Hi ILCs in the 
colon lamina propria as evaluated by FACS 
analysis. (C) Total numbers of IL-17A– or IFN-
–producing ILCs from the colon of indicated 
mice groups. (D) Cytokine production by cLPLs 
after overnight culture in complete medium 
alone (n/a) or in the presence of 10 ng/ml IL-23. 
Data are represented as mean ± SEM from 2 
pooled independent experiments (n = 6–11). 
(E) Il23r expression by cLPLs as evaluated by 
qRT-PCR. Data are normalized on Hprt expres-
sion. (F and G) 129SvEv Rag2/ mice were 
infected with H. hepaticus for 8 wk and 
CD45+linSca1+Thy1.2Hi ILCs were FACS 
sorted from the colon. (F) ILCs were cultured 
overnight in complete medium alone (n/a) or 
in the presence of 10 ng/ml IL-1. Il23r and 
Rorc expression levels were evaluated by qRT-
PCR and normalized on Hprt expression. Data 
are shown as mean ± SEM from 2 pooled independent experiments. In each experiment, 10–18 mice were pooled. (G) ILCs were cultured overnight in 
complete medium alone (n/a) or in the presence of 10 ng/ml IL-23. Il1r1 expression was evaluated by qRT-PCR and normalized on Hprt expression. Data 
are shown as mean ± SEM from two pooled independent experiments. In each experiment, 10–18 mice were pooled. *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001.
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reductions in secretion of the proinflammatory cytokines IL-6, 
IFN-, TNF and IL-17A by cLPLs (Fig. 5 G), indicating a 
general dampening of the intestinal inflammatory response in 
the absence of IL-1R signaling on T cells.
IL-1R1 signaling promotes accumulation  
and survival of Th17 cells in the colon
We next analyzed the effects of cell-specific IL-1R signals 
on the accumulation of CD4+ T cells in the colon. When 
compared with recipients of WT naive CD4+ T cells, 
C57BL/6 Rag1/ mice that received Il1r1/ naive CD4+ 
T cells exhibited a 50% decrease in the number of CD4+  
T cells present in the colon (Fig. 6 A), suggesting that IL-1R 
expression by T cells is essential to drive their accumulation 
in the intestine. Moreover, the effect of IL-1R signaling on 
accumulation of CD4+ T cells was specific to the intestine, 
because similar CD4+ T cell numbers were found in the 
MLN or spleen of C57BL/6 Rag1/ mice receiving WT 
or Il1r1/ naive CD4+ T cells (Fig. 6 A).
The T cell transfer model of colitis is characterized by ac-
cumulation of Th1 and Th17 cells in the colon (Hue et al., 
2006; Izcue et al., 2006). Recently, it has been proposed that 
in rapid colitis and systemic cachexia (Powrie et al., 1993). 
Intestinal inflammation in this model of colitis was associated 
with increased levels of IL-1 secretion by cLPLs (Fig. 5 A). 
To assess the requirement for IL-1 stimulation of T cells in 
intestinal inflammation, we transferred naive CD4+CD45RBHi 
T cells isolated from either WT or Il1r1/ mice into C57BL/6 
Rag1/ recipients and assessed the development of pathol-
ogy. As expected, adoptively transferred WT naive CD4+ 
T cells induced weight loss and severe intestinal and systemic 
inflammation in C57BL/6 Rag1/ recipients (Fig. 5, B–F). 
In contrast, Il1r1/ naive CD4+ T cells failed to induce 
weight loss upon transfer to C57BL/6 Rag1/ mice com-
pared with recipients of WT naive CD4+ T cells (Fig. 5 B). 
Moreover C57BL/6 Rag1/ mice transferred with Il1r1/ 
naive CD4+ T cells showed significantly reduced intestinal 
pathology in both the cecum and the colon (Fig. 5, C–E). 
Despite attenuated intestinal inflammation, no significant 
difference was observed in either splenomegaly or spleen cel-
lularity in C57BL/6 Rag1/ mice receiving WT or Il1r1/ 
naive CD4+ T cells (Fig. 5 F). The attenuated intestinal inflam-
mation in the colon of C57BL/6 Rag1/ mice receiving 
Il1r1/ naive CD4+ T cells was accompanied by significant 
Figure 5. T cell–driven intestinal inflammation is attenuated in the absence of IL-1R signaling. (A) C57BL/6 Rag1/ mice were transferred with 
4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT mice and culled at the development of clinical signs of disease. cLPLs were isolated from the  
colon and cultured overnight in complete medium. IL-1 secretion in the supernatants was evaluated by FlowCytoMix kit (eBioscience; mean ± SEM; n = 5 
for C57BL/6 Rag1/ mice and n = 10 for recipients of CD4+CD45RbHi T cells from 2 independent experiments). (B–G) C57BL/6 Rag1/ mice were trans-
ferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1/ mice. (B) Representative weight loss curve, shown as percentage of initial 
weight (data are shown as mean ± SEM; n = 8 mice/group, 1 representative of 3 independent experiments). (C and D) Intestinal inflammation scores for 
the colon (C) and the cecum (D) from three pooled independent experiments. Bars show the mean score. (E) Representative photomicrographs of colon 
and cecum (bar, 200 µm). (F) Spleen weight and spleen cell number. 1 representative experiment out of 3 is shown (n = 3 for untreated controls and n = 8 
for naive CD4+ T cell recipients). (G) Cytokine secretion by colonic lamina propria lymphocytes from C57BL/6 Rag1/ mice transferred with WT or 
Il1r1/ naive CD4+ T cells. Data are shown as mean ± SEM (n = 10–14 from 2 pooled independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
ND not detectable.
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in vitro culture with TGF- and IL-6, Il1r1/ T cells 
exhibited decreased differentiation into Th17 cells when 
compared with WT CD4+ T cells (Fig. 6 B). To assess the 
IL-1 plays a key role in promoting the differentiation of 
Th17 cells (Sutton et al., 2006; Chung et al., 2009; Sutton et al., 
2009). In agreement with these findings, we found that after 
Figure 6. Impaired Th17 accumulation in the gut in the absence of IL-1R1 signaling. (A) C57BL/6 Rag1/ mice were transferred with 4 × 105 
CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1/ mice. At sacrifice, CD4+ T cells in the colon, MLN and spleen were evaluated by FACS analysis. 
Data are shown as mean ± SEM (n = 20–21 from 3 pooled independent experiments). (B) Total CD4+ T cells were isolated from the spleen of WT or 
Il1r1/ mice and cultured in the presence of 2.5 ng/ml TGF- and 50 ng/ml IL-6, plus plate-bound CD3 (2 µg/ml) and CD28 (1 µg/ml). After 3 d, the 
frequency of IL-17A–producing cells was analyzed by intracellular staining. Data are shown as mean ± SD from 2 pooled independent experiments  
(n = 4), together with representative FACS plots (gated on CD4+TCR+ cells). (C–E) C57BL/6 Rag1/ mice were transferred with 4 × 105 CD4+ CD25 
CD45RBHi T cells from C57BL/6 WT or Il1r1/ mice. (C and D) At sacrifice, colonic lamina propria leukocytes were isolated and analyzed by intracellular 
FACS analysis. (C) Frequency of indicated T helper subsets among CD4+ T cells. In the representative FACS plot shown on the right, data are gated on 
CD4+TCR+ cells. (D) Accumulation of effector CD4+ T cell populations in the colon. Data are shown as mean ± SEM (n = 20–21 from 3 pooled indepen-
dent experiments). (E) CD4+ T cells were FACS sorted from the colon of recipients of Il1r1/ or WT naive CD4+ T cells and restimulated overnight with 
PMA and ionomycin. Cytokine secretion in the supernatants was assessed by FlowCytomix (n = 12–14 from 3 pooled independent experiments).  
(F) C57BL/6 Rag1/ mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or csf2/ mice and culled at development of 
clinical signs of disease. Colonic inflammation score was assessed histologically (n = 7–10). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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T cells revealed similar CFSE dilution profiles 12 d after 
transfer (unpublished data), suggesting that Il1r1/ T cells 
undergo comparable early expansion after adoptive transfer. 
Alternatively, we hypothesized that the absence of IL-1R 
signals could compromise the ability of CD4+ T cells to mi-
grate to the colon. To test this hypothesis, we transferred 
Il1r1/ or WT CD4+CD45RBHi T cells into C57BL/6 
Rag1/ mice and sacrificed them 2 wk after transfer, before 
the onset of colitis. At this early time point, no difference in 
the total number of CD4+ T cells or Th17 cells present in the 
colon was observed between C57BL/6 Rag1/ mice receiv-
ing Il1r1/ or WT naive CD4+ T cells (Fig. 7 B). Moreover, 
Ki67 expression by total CD4+ T cells or by Th17 cells was 
again comparable in WT and Il1r1/ CD4+ T cells (unpub-
lished data). In addition, Il1r1/ CD4+ T cells exhibited 
comparable expression of the chemokine receptors Ccr6, 
Ccr2, Ccr5, and Cxcr6 (Fig. 7 C). Together, these results ex-
cluded an effect of IL-1R expression in preventing T cell mi-
gration to the colon or in impairing early T cell proliferation.
We therefore hypothesized that the defective accumula-
tion of naive Il1r1/ CD4+ T cells could be caused by im-
paired survival. To assess this point, we first tried to quantify 
apoptotic T cells in vivo by staining colonic sections from 
colitic mice by terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) or caspase-3 staining combined 
with CD3 immunofluorescence staining. However, the fre-
quency of CD3+ apoptotic cells in these assays was too low to 
allow accurate quantification of apoptotic events, probably 
reflecting the rapid clearance of apoptotic cells in vivo 
(unpublished data). Therefore, we FACS sorted CD4+ T cells 
from the colon of C57BL/6 Rag1/ mice receiving either 
WT or Il1r1/ naive CD4+ T cells and assessed the expres-
sion of the antiapoptotic factors Bcl2 and Bclxl by qRT-PCR. 
Our analysis showed that colonic CD4+ T cells from mice re-
ceiving Il1r1/ naive CD4+ T cells expressed significantly 
lower levels of Bcl2 and Bclxl compared with those from mice 
transferred with WT naive CD4+ T cells (Fig. 7 D). Further-
more, Il1r1/ CD4+ T cells exhibited significantly higher 
levels of apoptosis than WT CD4+ T cells after stimulation 
with CD3 and CD28 mAb in vitro (Fig. 7 E), supporting 
the hypothesis that IL-1R1 signaling promotes T cell survival 
during inflammation, by preventing activation-induced apop-
tosis. In contrast, stimulation of freshly isolated ILCs with 
IL-1 did not affect their expression of Bcl2 (Fig. 7 F).
T cell–specific IL-23R signals are also required for intes-
tinal inflammation, as Il23r/ naive CD4+ T cells failed to 
induce intestinal pathology upon T cell transfer to C57BL/6 
Rag/ mice (Ahern et al., 2010). Initially, we hypothesized 
that, similar to ILCs, T cells required Il1r1 signals to up-
regulate Il23r expression. However, FACS sorted CD4+ T cells 
from the colon of mice transferred with either WT or Il1r1/ 
naive CD4+ T cells expressed similar levels of IL-23R (Fig. 8 A). 
Because it has been reported that IL-1R1 expression is up-
regulated in Th17 cells (Chung et al., 2009), we conjectured 
that in the colon this might be driven by IL-23, which is key 
for the generation of colitogenic CD4+ T cell responses 
role of IL-1R expression on T helper cell differentiation 
in vivo, we isolated CD4+ T cells from the colon of C57BL/6 
Rag1/ mice receiving WT or Il1r1/ naive CD4+ T cells 
and performed intracellular staining for IL-17A and IFN- 
production. We found that IL-1R expression was dispensable 
for Th1 and Th17 cell differentiation in the colon, as shown 
by similar frequencies of these effector cells observed in re-
cipients of WT or Il1r1/ naive CD4+ T cells (Fig. 6 C). 
IL-1R expression was also dispensable for Th17 differentia-
tion in the MLN (not depicted). Furthermore, we observed 
similar numbers of CD4+ IL-17AIFN-+ Th1 cells and IL-
17A+IFN-+ T cells in the colon of C57BL/6 Rag1/ mice 
receiving Il1r1/ or WT naive CD4+ T cells (Fig. 6 D). In 
contrast, we observed a specific defect in the accumulation of 
IL-17A–producing CD4+ T cells, as shown by a 50% de-
crease in the number of IL-17A+ IFN- T cells found in the 
colon of C57BL/6 Rag1/ mice receiving Il1r1/ naive 
CD4+ T cells when compared with recipients of WT naive 
CD4+ T cells (Fig. 6 D). To further examine the role of IL-
1R1 signaling on T cell effector functions, we isolated CD4+ 
T cells from the colon of mice transferred either with WT or 
Il1r1/ naive CD4+ T cells and examined their cytokine 
profile ex vivo. In accordance with our previous data, co-
lonic Il1r1/ CD4+ T cells secreted less IL-17A, whereas the 
levels of IFN- secretion were unaffected (Fig. 6 E). To-
gether, these data indicate a role for T cell–specific IL-1R1 
signaling in promoting the accumulation of CD4+ T cells in 
the colon, with a specific defect in Th17 cells.
Recent reports show that IL-1 promotes GM-CSF pro-
duction by Th17 cells, and that GM-CSF plays a key role in 
development of experimental autoimmune encephalomyelitis 
(EAE; Codarri et al., 2011; El-Behi et al., 2011). We found 
that colonic Il1r1/ CD4+ T cells isolated after T cell trans-
fer secreted significantly less GM-CSF than colonic WT CD4+ 
T cells (Fig. 6 E), prompting us to assess the role of T cell– 
derived GM-CSF in promoting intestinal inflammation. To 
this purpose, we adoptively transferred GM-CSF–deficient 
(csf2/) naive CD4+CD45RBHi T cells to C57BL/6 Rag1/ 
mice. We observed that the level of colonic inflammation 
was similar between mice receiving WT or csf2/ naive 
CD4+ T cells (Fig. 6 F). Cecal inflammation and splenomeg-
aly were also unaffected by the inability of naive T cells to pro-
duce GM-CSF, and the proportions and numbers of 
IL-17A+IFN-, IL-17A+IFN-+ and IL-17AIFN-+ effec-
tor CD4+ T cells were similar in recipients of csf2/ and WT 
naive T cells (unpublished data). These data indicate that T cell–
derived GM-CSF is not required to induce intestinal inflam-
mation or to facilitate Th17 cell differentiation in the gut.
Next, we examined whether the defective accumulation 
of Th17 cells in the absence of cell-specific IL-1R expression 
could be caused by defective proliferation of the Il1r1/  
T cells in the colon. However, CD4+ T cells and Th17 cells 
isolated from the colon of C57BL/6 Rag1/ mice receiving 
Il1r1/ or WT naive CD4+ T cells expressed the prolifera-
tion marker Ki67 to a similar extent (Fig. 7 A). Moreover, 
adoptive transfer of CFSE-labeled Il1r1/ or WT naive 
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Figure 7. IL-1R signaling modulates CD4+ T cell apoptosis in vivo and in vitro. (A) C57BL/6 Rag1/ mice were transferred with 4 × 105 CD4+ CD25 
CD45RBHi T cells from C57BL/6 WT or Il1r1/ mice. At sacrifice, cLPLs were isolated and Ki67 expression by cLPLs CD4+ T cells was assessed by intracellular stain-
ing. Data represent mean ± SEM (n = 20–21 from 3 pooled independent experiments). Representative FACS plots (gated on CD4+ T cells) and quantitation are 
shown. (B) C57BL/6 Rag1/ mice were transferred with 2 × 106 CD4+ CD25 CD45RbHi T cells from C57BL/6 WT or Il1r1/ mice and sacrificed 2 wk after trans-
fer. Total number of CD4+ T cells and Th17 cells from the colonic lamina propria were assessed by FACS. Data are shown as mean ± SEM (n = 5 mice/
group). (C and D) C57BL/6 Rag1/ mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1/ mice. Mice were sacrificed 
when recipients of WT naive CD4+ T cells developed clinical signs of colitis, and CD4+ T cells were FACS sorted from cLPL preparations. (C) Expression levels of 
indicated chemokine receptors as revealed by qRT-PCR analysis. (D) Bcl-2 and Bcl-XL expression by WT or Il1r1/ CD4+ T cells upon ex vivo restimulation with  
0.1 µg/ml PMA and 1 µg/ml ionomycin overnight in complete medium (n = 5 mice/group, 1 representative experiment out of 2 is shown). (E) Purified CD4+ T cells 
from WT or Il1r1/ mice were cultured for 3 d in the presence of plate-bound CD3 and CD28 mAb at the indicated concentrations. After staining with the 
phosphatidylserine-binding protein Annexin V and the vital dye 7AAD, Annexin V+ 7AAD cells were identified as early apoptotic events. The average frequency of 
Annexin V+ 7AAD cells in WT cells was set as a baseline (100%), and data were expressed as relative increase over baseline (n = 10 from 4 pooled independent 
experiments). Representative FACS plots (gated on CD4+ T cells) and quantitation are shown. (F) 129SvEv Rag2/ mice were infected with H. hepaticus for 8 wk. 
CD45+lin Sca1+Thy1.2Hi ILCs were FACS sorted from the colon and cultured overnight in complete medium alone (n/a) or in the presence of IL-1 (10ng/ml). Bcl2 
expression was evaluated by qRT-PCR and normalized on Hprt expression. Data are shown as mean ± SEM from two pooled independent experiments. In each 
experiment, 10–18 mice were pooled.
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of innate immune inflammation, by promoting the recruit-
ment of granulocytes to the colon. In addition, we showed 
that IL-1 stimulation of CD4+ T cells was required for the 
induction of intestinal inflammation in a T cell transfer model 
of colitis by promoting the accumulation and survival of 
CD4+ T cells in the colon. Moreover, we observed a crucial 
role for IL-1 in inducing “type-17” responses from both 
innate and adaptive leukocytes in the colon.
Using a T cell–independent model of colitis, we assessed the 
role of IL-1 in driving innate intestinal inflammation. In ac-
cordance with the central role played by IL-1 in orchestrating 
innate inflammatory responses (Dinarello, 1996; Sims and 
Smith, 2010), we observed attenuation of H. hepaticus–induced 
colitis after IL-1 treatment. The common adaptor protein, 
MyD88, is responsible for signaling downstream of the IL-1R 
(Dinarello, 2009) and previous studies from our laboratory 
showed MyD88/ mice to be completely protected from 
H. hepaticus–induced colitis (Asquith et al., 2010). Interestingly, 
H. hepaticus–infected MyD88/ mice were completely pro-
tected from typhlocolitis, whereas only colitis was significantly 
decreased in IL-1–treated mice, implying that IL-1 con-
tributes mainly to proinflammatory MyD88-dependent signals 
in the colon. Consistent with this hypothesis, H. hepaticus– 
infected 129SvEv Rag2/ mice treated with IL-1 exhibited 
a selective decrease in neutrophil recruitment in the colon. 
Others have reported that blocking the IL-1 pathway amelio-
rated DSS-triggered intestinal inflammation (Thomas et al., 
1991; Cominelli et al., 1992; Siegmund et al., 2001). IL-1R defi-
ciency in these models did not perturb granulocyte recruitment 
to the colon. However, DSS colitis represents an acute model of 
colitis where granulocyte recruitment is secondary to the exten-
sive epithelial damage caused by the initial bacterial or chemical 
injury. In contrast, H. hepaticus–induced intestinal pathology in 
129SvEv Rag2/ mice is primarily associated with chronic 
activation of innate leukocytes in the lamina propria (Asquith 
and Powrie, 2010; Asquith et al., 2010). Hence the mechanisms 
underlying intestinal pathology and leukocyte recruitment are 
profoundly different between these models of colitis.
Our data show that IL-1 acts to boost IL-17A production in 
the intestine of H. hepaticus–infected 129SvEv Rag2/ mice. 
(Ahern et al., 2010). To test this hypothesis, we co-transferred 
equal numbers of CD45.1+ WT and CD45.2+ Il23r/ naive 
CD4+ T cells into C57BL/6 Rag/ recipients and, after the 
development of colitis, we isolated colonic WT and Il23r/ 
CD4+ T cells by FACS sorting based on the expression of 
CD45.2. This strategy allows comparison of Il23r/ and 
WT CD4+ T cells that have been conditioned in an identical 
inflamed intestinal environment (Ahern et al., 2010). Analysis 
by qRT-PCR revealed that colonic Il23r/ CD4+ T cells 
expressed significantly lower levels of IL1r1 than colonic WT 
CD4+ T cells (Fig. 8 B), suggesting that T cell–specific IL-
23R signals promoted increased sensitivity to IL-1 in vivo. 
However, the levels of expression of the Th17 signature tran-
scription factor Rorc were similar between the two groups, 
suggesting that the observed reduction of IL-1R expression is 
not caused by a general impairment of Th17 differentiation 
in vivo (Fig. 8 B). Consistent with this hypothesis, Il23r/ 
naive CD4+ T cells failed to up-regulate IL1r1 when cultured 
under Th17 polarizing conditions (including IL-23) in vitro, 
whereas WT naive CD4+ T cells demonstrated a marked in-
crease in IL1r1 expression over the culture period (Fig. 8 C). 
Together, these data suggest that IL-23 signaling on T cells 
promotes IL-1R expression, thereby enhancing T cell sensi-
tivity to IL-1.
DISCUSSION
Numerous studies link intestinal inflammation in IBD pa-
tients with increased intestinal levels of IL-1. However, a 
lack of preclinical research into the role of IL-1 in promot-
ing chronic intestinal inflammation has hampered the transla-
tion of these clinical observations into potential therapeutic 
strategies, in spite of new evidence in humans linking dysreg-
ulated IL-1 secretion with polymorphisms associated to 
IBD development (Plantinga et al., 2011). Here, using two 
complementary models of intestinal inflammation, we have 
dissected the cellular mechanisms through which IL-1 con-
tributes to intestinal pathology. We found that IL-1 was essen-
tial for the development of severe innate immune pathology 
driven by the intestinal pathogen H. hepaticus. We identified 
an intestine-specific role for IL-1 in driving classical pathways 
Figure 8. IL-1R1 expression by colonic 
CD4+ T cells is dependent on IL-23 stimu-
lation. (A) C57BL/6 Rag1/ mice were trans-
ferred with 4 × 105 CD4+ CD25 CD45RBHi  
T cells from C57BL/6 WT or Il1r1/ mice. 
Mice were sacrificed when recipient of WT 
naive CD4+ T cells developed clinical signs of 
colitis. CD4+ T cells were FACS sorted from 
cLPL preparations and Il23r expression was 
evaluated by qRT-PCR (n = 5 mice/group,  
1 out of 2 representative experiments shown). (B) C57BL/6 mice were transferred with 1:1 mixtures of CD45.1+ (WT) and CD45.2+ (Il23r/) CD4+CD45RBhi 
T cells. Mice were sacrificed upon development of clinical signs of inflammation (6 wk) and WT or Il23r/ populations of T cells were FACS sorted 
based on the expression of CD45.2. Il1r1 and Rorc expression levels were evaluated by qRT-PCR (data are shown as mean ± SEM; n = 6 from 2 indepen-
dent experiments). (C) CD62LHi CD44low CD25 naive CD4+ T cells isolated from WT or Il23r/ mice were cultured under Th17-polarizing conditions. At 
the indicated time points, Il1r1 expression was evaluated by qRT-PCR (data are shown as mean ± SD; n = 2 from 2 pooled independent experiments).  
*, P < 0.05; **, P < 0.01.
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intestine and mediate colitis after transfer into C57BL/6 
Rag1/ mice, associated with reduced expression of Bcl2 
and Bcl-xL (Fukata et al., 2008; Tomita et al., 2008; 
Asquith et al., 2010). Overall, these data suggest that IL-1R/
Myd88 signaling is crucial to promote T cell survival during 
intestinal inflammation.
Defective CD4+ T cell accumulation in the intestine after 
transfer of naive Il1r1/ CD4+ T cells was primarily caused 
by decreased numbers of Th17 cells. Previous studies in 
humans and mice have identified a role for IL-1 in promot-
ing Th17 differentiation, and autoinflammatory diseases 
characterized by high levels of IL-1 are associated with a 
marked Th17 signature at the effector site (Horai et al., 2000; 
Aksentijevich et al., 2009; Brydges et al., 2009; Meng et al., 
2009; Reddy et al., 2009; Lamacchia et al., 2010). Addition-
ally, in vitro studies demonstrated a clear role for IL-1, in 
conjunction with the proinflammatory cytokines IL-6 and 
IL-23, in promoting the differentiation of Th17 cells (Sutton 
et al., 2006, 2009; Chung et al., 2009; Ghoreschi et al., 2010), 
and Il1r1/ mice show defective Th17 differentiation in the 
small intestine at steady state (Shaw et al., 2012). Further-
more, T cell–specific IL-1R expression is necessary for the 
induction of EAE in vivo, as adoptive transfer of Il1r1/ 
T cells resulted in decreased frequencies of Th17 cells in the 
central nervous system (Sutton et al., 2006; Chung et al., 
2009). Our in vitro studies confirmed the requirement for 
IL-1R expression in Th17 differentiation. However, compa-
rable frequencies of IL-17–producing CD4+ T cells were 
found in the colon of C57BL/6 Rag1/ mice receiving WT 
or Il1r1/ naive CD4+ T cells, which may reflect the highly 
polarizing Th17 microenvironment in the colon (Atarashi 
et al., 2008; Ivanov et al., 2009). Although dispensable for 
Th17 differentiation in the gut upon naive T cell transfer, 
IL-1R signaling was necessary to promote Th17 accumula-
tion, as shown by the decreased numbers of Th17 cells found 
in the colon of C57BL/6 Rag1/ mice receiving Il1r1/ 
naive CD4+ T cells. This effect was specific to Th17 cells and 
was not observed for IL-17A IFN-+ or IL-17A+ IFN-+ 
CD4+ T cells, showing that Il1r1/ T cells are not generally 
impaired in their proinflammatory capacity. This could be 
explained by high levels of expression of Il1r1 by Th17 cells, 
which may render them more sensitive to, or dependent on, 
IL-1R stimulation (Chung et al., 2009; Guo et al., 2009). 
Because proliferation and migration to the gut of Il1r1/ 
naive CD4+ T cells was unimpaired, it is possible that the 
main function for IL-1R signals in modulating Th17 biology 
in the gut is to promote their survival during inflammation. 
This hypothesis is consistent with other studies showing that 
IL-1 can promote Th17 expansion and cytokine produc-
tion in vitro in the absence of TCR stimulation (Sutton et al., 
2006), suggesting a role of IL-1 in homeostatic maintenance 
of Th17 cells.
We also present evidence of synergy between IL-23R and 
IL-1R signals for the induction and maintenance of patho-
genic Th17 responses. A previous in vitro study reported that 
IL-1R signaling only modestly enhanced Il23r expression by 
Given that IL-17A production contributes to pathology 
in this model (Buonocore et al., 2010), it is possible that 
the decreased inflammation observed after treatment with 
IL-1 is due, at least in part, to its effects on IL-17A. We 
further observed that IL-1 was required for the accumula-
tion of a novel population of IL-17A–producing ILCs, which 
express high levels of IL-1R1. Fewer numbers of Sca1+ 
Thy1.2Hi ILCs were present in the colon of H. hepaticus–
infected 129SvEv Rag2/ mice receiving IL-1 compared 
with those treated with an isotype control. In addition, ILCs 
isolated from the colon of H. hepaticus–infected 129SvEv 
Rag2/ mice that were treated with IL-1 had reduced 
frequencies of IL-17A– and IFN-–secreting cells, which 
correlated with decreased secretion of these cytokines in re-
sponse to IL-23 stimulation. Thus, IL-1 signals promote the 
accumulation and effector functions of ILCs in the intestine. 
A role for IL-1 in promoting the in vitro proliferation and 
function of a distinct innate lymphoid cell type has been pro-
posed. NK-22 or RORt+CD127+ NK-like cells are present 
at mucosal sites and can secrete both IL-22 and IL-17A in re-
sponse to IL-23 (Cella et al., 2009; Cupedo et al., 2009). 
Recently, it has been shown that IL-1 can strongly synergize 
with other cytokines, such as IL-7, IL-15, or IL-23, to pro-
mote proliferation and effector cytokine secretion by NK-22 
cells in vitro (Cella et al., 2010; Hughes et al., 2010; Reynders 
et al., 2011). Thus, IL-1 may play a crucial role in modulat-
ing the functions of several types of innate lymphoid cells at 
mucosal sites. The exact mechanisms underlying these effects 
remain unclear, but it is possible that IL-1 acts in concert 
with other factors to regulate ILC function, as IL-1 stimula-
tion alone has only minor effects on innate lymphoid cell 
biology (Cupedo et al., 2009; Hughes et al., 2010). In support 
of this hypothesis, we found that ILCs cultured with IL-1 
had significantly higher levels of Il23r expression than those 
cultured with medium alone, suggesting that IL-1R1 signals 
maintain or enhance IL-23 responsiveness in ILCs.
The ability of IL-1 to promote accumulation of immune 
effector cells in the intestine was paralleled in our studies using 
a T cell–dependent colitis model. The reduced ability of 
Il1r1/ naive CD4+ T cells to induce severe colitis upon 
transfer to C57BL/6 Rag1/ recipients was associated with 
reduced accumulation of CD4+ T cells. Remarkably, the 
accumulation defect was restricted to the intestine, with sim-
ilar numbers of CD4+ T cells found in the spleen or MLN in 
recipients of Il1r1/ CD4+ T cells. This would suggest that 
although not required for the reconstitution of lymphopenic 
mice, T cell–specific IL-1R signaling is a prerequisite for T cell 
accumulation in the intestine. Mechanistic analysis revealed 
that this effect was not caused by defective proliferation or 
migration of Il1r1/ T cells, suggesting a role of IL-1 in 
promoting T cell survival. This hypothesis was confirmed by 
the observation that the expression of the antiapoptotic pro-
teins Bcl-2 and Bcl-xL was impaired in colonic Il1r1/ CD4+ 
T cells after transfer to lymphopenic mice. These results are 
consistent with previous findings that naive MyD88/ CD4+ 
T cells also exhibited impaired ability to accumulate in the 
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Procedures Act (1986) under a Project License (PPL) authorized by the UK 
Home Office Animal Procedures Committee and approved by the Sir William 
Dunn School of Pathology Local Ethical Review Committee. C57BL/6 
csf2/ mice were provided by B. Becher (University of Zurich, Zurich, 
Switzerland). Mice were routinely screened for Helicobacter spp. and were 
>6 wk of age when used.
Bacteria. H. hepaticus NCI-Frederick isolate 1A, isolated from the same mouse 
colony as isolate Hh-1 (strain 51449; American Type Culture Collection), was 
grown on blood agar plates containing Trimethoprim, vancomycin, and poly-
mixin B (Oxoid) under microaerophilic conditions, as previously described 
(Maloy et al., 2003; Young et al., 2004). H. hepaticus viability was confirmed 
using fluorescent microscopy with a bacterial live/dead kit (BacLight; Invitro-
gen). For induction of innate immune colitis, 129SvEv Rag2/ mice were in-
fected with H. hepaticus (108 CFU) by oral gavage three times on alternate 
days. H. hepaticus–infected mice were sacrificed 8–10 wk after infection.
In vivo antibody treatment. To block IL-1 activity in vivo, H. hepaticus–
infected 129SvEv Rag2/ mice were injected i.p. with 1 mg IL-1–blocking 
mAb (IL-1) or 1 mg isotype control mAb from the day of the first inocu-
lation with H. hepaticus, and treatment repeated weekly for the duration of 
the experiment.
Induction of colitis with naive CD4+CD45RBHi T Cells. Naive 
CD4+CD45RBHi T cells were purified (>98%) from spleens of C57BL/6, 
C57BL/6 Il1r1/, IL23r/, or Csf2/ mice via FACS sorting, as previ-
ously described (Izcue et al., 2008). In brief, single-cell suspensions were de-
pleted of CD8+, MHC class II+, Mac-1+, and B220+ cells by negative selection 
using a panel of rat monoclonal antibodies, followed by sheep anti–rat–coated 
Dynabeads (Invitrogen). After staining with APC-conjugated CD4, PE-
conjugated CD25, and FITC–CD45RB, naive CD4+CD45RBHi T cells 
were purified by cell sorting with a cell sorter (MoFlo; Dako). Naive T cell 
suspensions were washed in sterile PBS, and age- and sex-matched C57BL/6 
Rag1/ recipient mice received 4 × 105 CD4+CD45RBHi T cells by i.p. in-
jection. For co-transfer experiments, 1:1 mixtures of CD45.2+ Il23r/ and 
CD45.1+ WT CD4+CD45RBHi T cells were injected i.p. (total cell number = 
4 × 105). Mice were sacrificed when symptoms of clinical disease (weight loss 
and/or diarrhea) developed in control groups, 5–8 wk after transfer of naive 
CD4+ T cells, unless otherwise indicated. For mice sacrificed 2 wk after 
transfer, 2 × 106 CD4+CD45RBHi T cells were transferred per mouse.
Assessment of intestinal inflammation. Samples of cecum and proximal, 
mid, and distal colon were prepared as previously described (Izcue et al., 
2008), and inflammation was graded according to the following scoring sys-
tem. Each sample was graded semiquantitatively from zero to three for four 
criteria: (1) degree of epithelial hyperplasia and goblet cell depletion; (2) leu-
kocyte infiltration in the lamina propria; (3) area of tissue affected; and (4) 
the presence of markers of severe inflammation such as crypt abscesses, sub-
mucosal inflammation, and ulcers. Scores for each criterion were added to 
give an overall inflammation score for each sample of 0–12. Scores from 
proximal, mid, and distal colon were averaged to obtain inflammation scores 
for the colon. Sections were scored in a blinded fashion to avoid bias.
Isolation of leukocyte subpopulations and FACS. Cell suspensions 
from spleen, liver, MLN, and the lamina propria were prepared as described 
previously (Buonocore et al., 2010). Cells were washed, incubated with 
anti-Fc receptor (CD16/32), and stained for flow cytometric analysis using 
combinations of the following antibodies: PeCy7-conjugated CD4 and 
PerCP-Cy5.5-conjugated TCR- (T cells) and FITC-conjugated CD45.2, 
CD11b conjugated to PE, and Gr1 conjugated to PerCP-Cy5.5 (innate 
cells). Intracellular staining was performed as previously described (Ahern et al., 
2010): cells were restimulated for 4 h with 0.1 µg/ml PMA (Sigma-Aldrich), 
1 µg/ml ionomycin (Sigma-Aldrich), and 10 µg/ml Brefeldin A (Insight 
Biotechnology), washed, and stained for surface markers. Cells were then 
fixed overnight in eBioscience Fix/Perm buffer at 4°C. Cells were washed 
CD4+ T cells (Chung et al., 2009). Similarly, we found that 
colonic CD4+ T cells isolated from C57BL/6 Rag1/ mice 
that received either WT or Il1r1/ naive CD4+ T cells ex-
pressed comparable levels of Il23r. In contrast, when CD4+  
T cells were isolated from the inflamed colon of C57BL/6 
Rag1/ mice that were co-transferred with both WT and 
Il23r/ naive CD4+ T cells, we found that the Il23r/ CD4+ 
T cells expressed significantly lower levels of Il1r1. Further-
more, Il23r/ naive CD4+ T cells failed to increase expression 
of Il1r1 during culture in IL-23–supplemented, Th17-polarizing 
conditions in vitro. Together, these observations suggest that 
IL-23R signals play a key role in the up-regulation and main-
tenance of IL-1R expression by Th17 cells. As IL-1R signals 
promote T cell survival, this process establishes a positive 
feedback loop promoting T cell accumulation in the colon.
Recent evidence suggests that IL-1 promotes GM-CSF 
production by Th17 cells and that T cell–derived GM-CSF 
plays a key role in EAE pathology (Codarri et al., 2011; El-Behi 
et al., 2011). Although we found that colonic CD4+ T cells iso-
lated from C57BL/6 Rag1/ mice receiving Il1r1/ CD4+ 
naive T cells showed reduced GM-CSF production, adoptive 
transfer of GM-CSF–deficient CD4+ naive T cells resulted in 
intestinal inflammation with similar features to that observed in 
C57BL/6 Rag1/ mice receiving WT CD4+ T cells. Hence, 
although necessary for the development of EAE, T cell–derived 
GM-CSF is not required for the induction of colitis.
In summary, our data clearly show an effect of blocking 
IL-1 in ameliorating chronic intestinal inflammation, as well 
as providing mechanistic insight into the proinflammatory 
actions of IL-1 in the intestine. This study also highlights the 
synergistic activities of IL-1 and IL-23 in promoting patho-
genic innate and adaptive type 17 responses in the intestine. 
This hypothesis is supported by the finding that IL-1 and 
IL-23 are expressed with similar kinetics during the develop-
ment of intestinal inflammation ((Boulard et al., 2012) and 
unpublished data) and by previous studies showing that IL-1 
and IL-23 promote a Th17-like phenotype in both CD4+  
T cells and NK-22 cells in vitro (Chung et al., 2009; Cella 
et al., 2010; Ghoreschi et al., 2010). Numerous IL-1–blocking 
reagents have been developed for clinical studies, many of 
which have proven successful in treating inflammatory dis-
orders (Gabay et al., 2010). Moreover, recent data show exacer-
bated IL-1 production upon NOD2 stimulation of PBMCs 
from IBD patients bearing a risk variant of the ATG16L1 
gene (Plantinga et al., 2011), confirming that IL-1 is a cen-
tral effector mechanism downstream of different IBD-related 
inflammatory pathways. Considering the profound dysregu-
lation of the IL-1 pathway observed in the gut of IBD pa-
tients, targeting this pathway may represent a future therapeutic 
approach in IBD.
MATERIALS AND METHODS
Mice. 129SvEv Rag/, C57BL/6, C57BL/6 Rag1/, C57BL/6 Il1r1/, 
and Il23r/ C57BL/6 strains were bred and maintained under specific 
pathogen–free conditions in accredited animal facilities at the University of 
Oxford. All experiments were performed in accordance with the UK Scientific 
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Cytokine detection. For cytokine detection, colonic lamina propria cells 
we cultured overnight in complete RPMI media. IL-6, IFN-, IL-17, TNF, 
and IL-1 levels in culture supernatants were measured using FlowCytomix 
Bead-based assay (eBioscience) and cytokine concentration was normalized 
to cell number. To assess innate lymphoid cell function, colonic lamina pro-
pria cells were cultured with or without recombinant IL-23 (10 ng/ml; 
R&D) overnight, and IL-17 and IFN- were measured in the supernatants 
as above. Organ explants were prepared as previously described (Hue et al., 
2006) and cultured overnight in complete RPMI media. IL-1 levels in the 
supernatants were determined by Bio-Plex Cytokine assay (Bio-Rad Laborato-
ries), and concentrations were normalized to the weight of the explants.
Statistics. The nonparametric Mann-Whitney test was used for assessment 
of statistical significance of in vivo experiments. The Student’s t test was used 
to assess the significance of in vitro experiments. Weight curves were compared 
using two-way ANOVA. Data were considered significant when P < 0.05.
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